Goodwin Procter advised Lacerta Therapeutics on the deal.Lacerta Therapeutics announced its AAV capsid licensing and research collaboration agreement with Prevail Therapeutics. As a part of the…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
